10351
|
Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 2008; 105:8061-6. [PMID: 18523011 PMCID: PMC2409137 DOI: 10.1073/pnas.0710929105] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2007] [Indexed: 12/14/2022] Open
Abstract
Nonmutated tissue differentiation antigens expressed by tumors are attractive targets for cancer immunotherapy, but the consequences of a highly effective antitumor immune response on self-tissue have not been fully characterized. We found that the infusion of ex vivo expanded adoptively transferred melanoma/melanocyte-specific CD8+ T cells that mediated robust tumor killing also induced autoimmune destruction of melanocytes in the eye. This severe autoimmunity was associated with the up-regulation of MHC class I molecules in the eye and high levels of IFN-gamma derived from both adoptively transferred CD8+ T cells and host cells. Furthermore, ocular autoimmunity required the presence of the IFN-gamma receptor on target tissues. Data compiled from >200 eyes and tumors in 10 independently performed experiments revealed a highly significant correlation (P < 0.0001) between the efficacy of tumor immunotherapy and the severity of ocular autoimmunity. Administration of high doses of steroids locally mitigated ocular autoimmunity without impairing the antitumor effect. These findings have particular importance for immunotherapies directed against self-antigens and highlight the need for targeting unique tumor antigens not expressed in critical tissues.
Collapse
Affiliation(s)
- Douglas C Palmer
- National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10352
|
Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother 2008; 57:799-811. [PMID: 17962942 PMCID: PMC11031088 DOI: 10.1007/s00262-007-0416-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2007] [Accepted: 10/09/2007] [Indexed: 12/21/2022]
Abstract
Tumor protein D52 (TPD52) is involved in transformation and metastasis and has been shown to be over-expressed in tumor cells compared to normal cells and tissues. Murine TPD52 (mD52) shares 86% protein identity with the human TPD52 orthologue (hD52). To study TPD52 protein as a target for active vaccination recombinant, mD52 was administered as a protein-based vaccine. Naïve mice were immunized with either mD52 protein and CpG/ODN as a molecular adjuvant or CpG/ODN alone. Two weeks following the final immunization, mice were challenged s.c. with syngeneic tumor cells that over-express mD52. Two distinct murine tumor cell lines were used for challenge in this model, mKSA and 3T3.mD52. Half of the mice immunized with mD52 and CpG/ODN rejected or delayed onset of mKSA s.c. tumor cell growth, and 40% of mice challenged with 3T3.mD52 rejected s.c. tumor growth, as well as the formation of spontaneous lethal lung metastases. Mice immunized with mD52 and CpG/ODN generated detectable mD52-specific IgG antibody responses indicating that mD52 protein vaccination induced an adaptive immune response. In addition, mice that rejected tumor challenge generated tumor-specific cytotoxic T lymphocytes' responses. Importantly, microscopic and gross evaluation of organs from mD52 immunized mice revealed no evidence of autoimmunity as assessed by absence of T cell infiltration and absence of microscopic pathology. Together, these data demonstrate that mD52 vaccination induces an immune response that is capable of rejecting tumors that over-express mD52 without the induction of harmful autoimmunity.
Collapse
Affiliation(s)
- Laura A. Payton
- Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 6591, Lubbock, TX 79430 USA
- Present Address: Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390 USA
| | - Jennifer D. Lewis
- Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 6591, Lubbock, TX 79430 USA
| | - Jennifer A. Byrne
- Discipline of Paediatrics and Child Health, Childrens Hospital at Westmead, The University of Sydney, Sydney, NSW Australia
| | - Robert K. Bright
- Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 6591, Lubbock, TX 79430 USA
| |
Collapse
|
10353
|
Nakamoto N, Kaplan DE, Coleclough J, Li Y, Kaminski M, Shaked A, Olthoff K, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM, Chang KM. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008; 134:1927-37, 1937.e1-2. [PMID: 18549878 PMCID: PMC2665722 DOI: 10.1053/j.gastro.2008.02.033] [Citation(s) in RCA: 233] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2007] [Accepted: 01/24/2008] [Indexed: 12/14/2022]
Abstract
BACKGROUND & AIMS The immunoinhibitory receptor programmed death-1 (PD-1) is up-regulated on dysfunctional virus-specific CD8 T cells during chronic viral infections, and blockade of PD-1/PD-ligand (PD-L) interactions can restore their function. As hepatitis C virus (HCV) persists in the liver with immune-mediated disease pathogenesis, we examined the role of PD-1/PD-L pathway in antigen-specific CD8 T-cell dysfunction in the liver and blood of HCV-infected patients. METHODS PD-1 expression and function of circulating CD8 T cells specific for HCV, Epstein-Barr virus, and influenza virus were examined ex vivo and following antigenic stimulation in vitro in patients with acute, chronic, and resolved HCV infection using class I tetramers and flow cytometry. Intrahepatic CD8 T cells were examined from liver explants of chronically HCV-infected transplant recipients. RESULTS Intrahepatic HCV-specific CD8 T cells from chronically HCV-infected patients were highly PD-1 positive, profoundly dysfunctional, and unexpectedly refractory to PD-1/PD-L blockade, contrasting from circulating PD-1-intermediate HCV-specific CD8 T cells with responsiveness to PD-1/PD-L blockade. This intrahepatic functional impairment was HCV-specific and directly associated with the level of PD-1 expression. Highly PD-1-positive intrahepatic CD8 T cells were more phenotypically exhausted with increased cytotoxic T-lymphocyte antigen 4 and reduced CD28 and CD127 expression, suggesting that active antigen-specific stimulation in the liver induces a profound functional exhaustion not reversible by PD-1/PD-L blockade alone. CONCLUSIONS HCV-specific CD8 T-cell dysfunction and responsiveness to PD-1/PD-L blockade are defined by their PD-1 expression and compartmentalization. These findings provide new and clinically relevant insight to differential antigen-specific CD8 T-cell exhaustion and their functional restoration.
Collapse
Affiliation(s)
- Nobuhiro Nakamoto
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA,Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
| | - David E. Kaplan
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA,Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
| | - Jennifer Coleclough
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA,Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
| | - Yun Li
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA,Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
| | - Mary Kaminski
- Department of Surgery, Penn Liver Transplant Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Abraham Shaked
- Department of Surgery, Penn Liver Transplant Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Kim Olthoff
- Department of Surgery, Penn Liver Transplant Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Emma Gostick
- Department of Medical Biochemistry and Immunology, Cardiff University School of Medicine, Cardiff CF14 4XN, UK
| | - David A. Price
- Department of Medical Biochemistry and Immunology, Cardiff University School of Medicine, Cardiff CF14 4XN, UK
| | - Gordon J. Freeman
- Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA
| | - E. John Wherry
- Immunology Program, The Wistar Institute, Philadelphia, PA
| | - Kyong-Mi Chang
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA,Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
| | | |
Collapse
|
10354
|
Abstract
Gonorrhea is the second most commonly reported infectious disease in the USA, and incidence has been increasing in recent years. Antibiotic resistance among clinical isolates has reached a critical point at which the CDC currently recommends only a single class of antibiotic for treatment. These developments have hastened the search for a vaccine to protect against gonococcal infections. Vaccine efforts have been thwarted by the ability of the gonococcus to antigenically vary most surface structures. The transferrin-iron transport system is not subject to high-frequency phase or antigenic variation and is expressed by all pathogenic Neisseria. Vaccine formulations comprised of epitopes of the transferrin-binding proteins complexed with inactivated cholera toxin generated antibodies with potentially protective characteristics. These antigens, and others predicted from genome sequence data, could be developed into a vaccine that protects against neisserial infections.
Collapse
Affiliation(s)
- C N Cornelissen
- Department of Microbiology & Immunology, Virginia Commonwealth University, PO Box 980678, Richmond, VA 23298-0678, USA.
| |
Collapse
|
10355
|
Abstract
A fundamental assumption usually made in causal inference is that of no interference between individuals (or units); that is, the potential outcomes of one individual are assumed to be unaffected by the treatment assignment of other individuals. However, in many settings, this assumption obviously does not hold. For example, in the dependent happenings of infectious diseases, whether one person becomes infected depends on who else in the population is vaccinated. In this article, we consider a population of groups of individuals where interference is possible between individuals within the same group. We propose estimands for direct, indirect, total, and overall causal effects of treatment strategies in this setting. Relations among the estimands are established; for example, the total causal effect is shown to equal the sum of direct and indirect causal effects. Using an experimental design with a two-stage randomization procedure (first at the group level, then at the individual level within groups), unbiased estimators of the proposed estimands are presented. Variances of the estimators are also developed. The methodology is illustrated in two different settings where interference is likely: assessing causal effects of housing vouchers and of vaccines.
Collapse
Affiliation(s)
- Michael G. Hudgens
- Michael G. Hudgens is Research Associate Professor, Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599 (E-mail: ). M. Elizabeth Halloran is Professor, Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, and Department of Biostatistics, University of Washington, Seattle, WA 98185 (E-mail: )
| | - M. Elizabeth Halloran
- Michael G. Hudgens is Research Associate Professor, Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599 (E-mail: ). M. Elizabeth Halloran is Professor, Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, and Department of Biostatistics, University of Washington, Seattle, WA 98185 (E-mail: )
| |
Collapse
|
10356
|
Abstract
BACKGROUND The growing concern over the emergence of antibiotic-resistant Helicobacter pylori infection is propelling the development of an efficacious vaccine to control this highly adaptive organism. AIM We studied the use of a dendritic cell (DC)-based vaccine against H. pylori infection in mice. METHODS The cellular immune responses to murine bone marrow-derived DCs pulsed with phosphate-buffered saline (PBS-DC) or live H. pylori SS1 (HP-DC) were assessed in vitro and in vivo. The protective immunity against H. pylori SS1 oral challenge was compared between HP-DC or PBS-DC immunized mice. The effect of regulatory T-cell (Treg) depletion by anti-CD25 antibody on HP-DC vaccine efficacy was also evaluated. RESULTS HP-DC induced a Th1-dominant response in vitro. In vivo, HP-DC immunized mice were characterized by a mixed Th1/Th2 peripheral immune response. However, in the stomach, HP-DC immunized mice expressed a higher level of IFN-gamma compared to PBS-DC immunized mice; no difference was found for interleukin-5 expressions in the stomach. A lower bacterial colonization post-H. pylori challenge was observed in HP-DC immunized mice compared to PBS-DC immunized mice with no significant difference in gastritis severity. H. pylori-specific Th1 response and protective immunity were further enhanced in vivo by depletion of Treg with anti-CD25 antibody. CONCLUSION DC-based anti-H. pylori vaccine induced H. pylori-specific helper T-cell responses capable of limiting bacterial colonization. Our data support the critical role of effector cellular immune response in the development of H. pylori vaccine.
Collapse
Affiliation(s)
- Min Zhang
- Department of Internal Medicine (Gastroenterology Division), University of Michigan, Ann Arbor, Michigan 48109
| | - Bradford E. Berndt
- Department of Internal Medicine (Gastroenterology Division), University of Michigan, Ann Arbor, Michigan 48109
| | - Kathryn A. Eaton
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan 48109
| | - Sivaprakash Rathinavelu
- Department of Internal Medicine (Gastroenterology Division), University of Michigan, Ann Arbor, Michigan 48109
| | - Anna Pierzchala
- Department of Internal Medicine (Gastroenterology Division), University of Michigan, Ann Arbor, Michigan 48109
| | - John Y. Kao
- Department of Internal Medicine (Gastroenterology Division), University of Michigan, Ann Arbor, Michigan 48109
| |
Collapse
|
10357
|
Qian F, Rausch KM, Muratova O, Zhou H, Song G, Diouf A, Lambert L, Narum DL, Wu Y, Saul A, Miller LH, Long CA, Mullen GED. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008; 26:2521-7. [PMID: 18423804 PMCID: PMC2426823 DOI: 10.1016/j.vaccine.2008.03.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2007] [Revised: 03/03/2008] [Accepted: 03/07/2008] [Indexed: 11/22/2022]
Abstract
Both the blood-stage protein apical membrane antigen 1 (AMA1) and the 25-kDa sexual-stage protein (Pfs25) of Plasmodium falciparum are two leading candidates in malarial vaccine development. We have previously demonstrated that conjugation of these malarial antigens to recombinant Pseudomonas aeruginosa ExoProtein A (rEPA) significantly increased the mean-specific functional antibody responses in mice; however, some mice responded poorly and were unable to demonstrate a functional response. We hypothesized that the immunogenicities of these two malarial antigens could be further enhanced by the inclusion of a CpG oligodeoxynucleotide in the formulation. Mice were immunized with either rEPA-conjugated or unconjugated AMA1 and Pfs25 formulated on Alhydrogel with or without the addition of CPG 7909. Mice received the formulations on days 0 and 28, and mouse sera were collected on day 42. ELISA analyses on these sera showed that the addition of CPG 7909 to AMA1-rEPA and Pfs25-rEPA formulated on Alhydrogel induced significantly higher mean antibody titers than the formulations without CPG 7909, and led to a mixed Th1/Th2 response as demonstrated by the production of mouse IgG1 and IgG2a subclasses. The presence of CPG 7909 in the formulations of both conjugated antigens greatly increased the proportion of responders with antibody titers sufficient to inhibit blood-stage parasite growth in vitro or block transmission of sexual-stage parasites to mosquitoes. The results obtained in this study indicate the potential use of a combination strategy to increase the number of responders to malarial antigens in humans.
Collapse
Affiliation(s)
- Feng Qian
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Kelly M. Rausch
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Olga Muratova
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Hong Zhou
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Guanhong Song
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Ababacar Diouf
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Lynn Lambert
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - David L. Narum
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Yimin Wu
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Allan Saul
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Louis H. Miller
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Carole A. Long
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
| | - Gregory E. D. Mullen
- Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
- * Corresponding author. Present mailing address: Division of Imaging Sciences, King’s College London, The Rayne Institute, 4th Floor, Lambeth Wing, St. Thomas’ Hospital, London, SE1 7EH Tel: + 44 20 7188 5440, fax: +44 20 7188 5442. E-mail address: (G.E.D. Mullen)
| |
Collapse
|
10358
|
Abstract
During 25 years of research since HIV-1 was first identified in Paris, there have been great advances in our understanding of the virus and of the immune system. Practical advances include the early development of diagnostic tests of infection that made blood donation safe, and since 1996, combination anti-retroviral therapy that has great reduced incidence of AIDS in HIV-infected people who have access to the drugs. HIV prevention through behavioural change has been successful, and we do not yet have any safe and efficacious microbicides or vaccines.
Collapse
Affiliation(s)
- R A Weiss
- Division of Infection and Immunity, University College London, London, UK.
| |
Collapse
|
10359
|
Labarthe MC, Theocharous P, Russell N, Todryk S, Bangma C, Thraves P, Dalgleish AG, Whelan MA. A novel murine model of allogeneic vaccination against prostate cancer. Cancer Immunol Immunother 2008; 57:453-65. [PMID: 17805533 PMCID: PMC11030044 DOI: 10.1007/s00262-007-0384-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2007] [Accepted: 07/30/2007] [Indexed: 10/22/2022]
Abstract
Prostate cancer continues to be a major cause of death in men. Surgical and medical treatments of the disease have improved, but metastasic disease remains a significant clinical problem. Novel therapies such as whole cell vaccination offer the potential of treating disease by stimulating the immune system. To study the efficacy of a whole cell vaccine in prostate cancer two strains of mice were used: C57BL/6 (H-2Kb) and C3H/HeJ (H-2K(k)) in combination with four different cell lines. Thus, a model was constructed of allogeneic and syngeneic vaccine, as well as a challenge tumour for each strain. Two novel cell lines were developed during this study. Firstly, the non tumourigeneic PMC-1 was derived from a normal mouse prostate and immortalized with HPV16. Secondly, the tumourigeneic PMC-1 C6ras1p1 was transformed with human ras gene which formed tumours in both SCID and C3H/HeJ mice. Protection, and the nature of the immune response to syngeneic and allogeneic vaccine, in males and females was examined in both strains. Vaccination with both syngeneic and allogeneic irradiated whole cell vaccines induced protection from syngeneic challenge in females. However, no protection was observed when allogeneic vaccine was given to male mice. This correlated with the immune response. Two types of cellular immune responses were generated in females. A NK-mediated response was observed in C57BL/6 mice, whilst C3H/HeJ mice developed a CTL response. Little or no cellular immune response was observed in males. The cytokine profile in C3H/HeJ females was a mixture of Th1 and Th2 whilst a mainly Th1 profile was observed in C57BL/6 mice. Male mice showed a diminished cytokine secretion compared to females which was further depressed after challenge. The difference in immunity was largely as expected, since tolerance to prostate antigens should not normally develop in female mice. However, this makes this model particularly relevant clinically since it directly mimics the human situation and thus may accelerate the development of whole cell vaccines for clinical use.
Collapse
Affiliation(s)
- M-C Labarthe
- Department of Oncology, Cellular and Molecular Medicine, St George's University of London, Cranmer Terrace, London SW17 0RE, UK.
| | | | | | | | | | | | | | | |
Collapse
|
10360
|
de Cássia Figueira Silva R, do Nascimento ER, de Almeida Pereira VL, Barreto ML, do Nascimento MDGF. Mycoplasma synoviae infection on Newcastle disease vaccination of chickens. Braz J Microbiol 2008; 39:384-9. [PMID: 24031234 PMCID: PMC3768380 DOI: 10.1590/s1517-838220080002000033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2007] [Revised: 11/05/2007] [Accepted: 04/29/2008] [Indexed: 11/21/2022] Open
Abstract
Newcastle disease is characterized by respiratory manifestations in association with nervous and/or digestive symptoms. Its prevention is done by vaccination with live attenuated (lentogenic strains) and/or killed vaccines. The lentogenic strains can lead to strong post-vaccination reaction, principally due to the presence of other pathogenic agents. Among them, Mycoplasma synoviae is worldwide important, mainly in Brazil. The dissemination of this agent in poultry flocks has been achieved due to difficulties in diagnosis and disease reproduction, virulence variations among different M.synoviae strains, and attribution of typical M.synoviae disease manifestation to other disease agents. This experimental study in SPF chicks (Gallus gallus), previously infected by M.synoviae and thereafter vaccinated against Newcastle disease, was done with the objective of evaluating M.synoviae pathogenicity through assessment of post-vaccinal respiratory reactions and serologic responses to Newcastle disease virus vaccine in the absence of environmental factors. A total of 86 three days old chicks were used, being 57 infected by eye and nostril drop, with chicken activated M. synoviae strain WVU 1853. Seven days later, 21 mycoplasma infected birds plus 29 not mycoplasma infected ones were vaccinated against Newcastle disease. As results, the not infected and vaccinated birds yielded, significantly, higher and longer lasting serologic responses to Newcastle disease vaccine virus than those infected and vaccinated. Similarly, the infected and vaccinated birds yielded lower serologic reactions to M.synoviae than those only mycoplasma infected. No post-vaccinal respiratory reaction was observed in the vaccinated birds.
Collapse
|
10361
|
Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008; 2:97-105. [PMID: 19707432 PMCID: PMC2727782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix() is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.
Collapse
Affiliation(s)
| | - Chien-Fu Hung
- Departments of Pathology, Obstetrics and Gynecology
| | - Richard Roden
- Departments of Pathology, Obstetrics and Gynecology, Oncology
| | - T-C Wu
- Departments of Pathology, Obstetrics and Gynecology, Molecular Microbiology and Immunology, Oncology,Correspondence: T-C Wu, Department of Pathology, Johns Hopkins Hospital, CRB II Room 309, 1550 Orleans Street, Baltimore, Maryland 21231, USA, Tel +1 410 614 3899, Fax +1 443 287 4295, Email
| |
Collapse
|
10362
|
Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, MacRae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005-10. [PMID: 18287062 PMCID: PMC2268575 DOI: 10.1073/pnas.0712237105] [Citation(s) in RCA: 493] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Indexed: 12/11/2022] Open
Abstract
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients increases immune-mediated tumor destruction in some subjects. Nonetheless, patients that respond also frequently manifest serious inflammatory pathologies, raising the possibility that the therapeutic and toxic effects of CTLA-4 blockade might be linked. Here we show that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients. The application of this sequential immunotherapy to advanced ovarian carcinoma patients also revealed that tumor destruction and severe inflammatory pathology could be dissociated, although further refinements are required to increase clinical responses and to minimize toxicity in this population. The extent of therapy-induced tumor necrosis was linearly related to the natural logarithm of the ratio of intratumoral CD8(+) effector T cells to FoxP3(+) regulatory T cells (Tregs) in posttreatment biopsies. Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.
Collapse
Affiliation(s)
- F. Stephen Hodi
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | - Marcus Butler
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | | | - Michael V. Seiden
- Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
| | - Frank G. Haluska
- Cancer Center and Division of Hematology/Oncology, Tufts–New England Medical Center, Boston, MA 02111
| | - Andrea Kruse
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | - Suzanne MacRae
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | - Marybeth Nelson
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | - Christine Canning
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | - Israel Lowy
- Medarex, Inc., 67 Beaver Avenue, Annandale, NJ 08801
| | - Alan Korman
- Medarex, Inc., 67 Beaver Avenue, Annandale, NJ 08801
| | - David Lautz
- Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
| | - Sara Russell
- Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
| | - Michael T. Jaklitsch
- Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
| | - Nikhil Ramaiya
- Department of Radiology, Dana–Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| | - Teresa C. Chen
- Massachusetts Eye and Ear Infirmary and Harvard Medical School, 243 Charles Street, Boston, MA 02114
| | - Donna Neuberg
- Department of Biostatistics and Computational Biology, Dana–Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115; and
| | - James P. Allison
- Howard Hughes Medical Institute and Program in Immunology, Memorial Sloan–Kettering Cancer Institute, New York, NY 10021
| | | | - Glenn Dranoff
- Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115
| |
Collapse
|
10363
|
Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN. Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel. Vaccine 2008; 26:869-73. [PMID: 18206278 PMCID: PMC2268034 DOI: 10.1016/j.vaccine.2007.11.085] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2007] [Revised: 11/26/2007] [Accepted: 11/29/2007] [Indexed: 10/22/2022]
Abstract
The seroconversion rates and geometric mean concentrations (GMC) of IgG anti-PA for stored sera from U.S. military personnel immunized 3, 4, and 6 times with the U.S. licensed anthrax vaccine adsorbed were studied. Anti-PA IgG concentrations were measured by ELISA. All 246 vaccinees had low but detectable pre-immunization anti-PA IgG (GMC 1.83 microg/mL). Three doses elicited a GMC of 59.92 microg/mL and a seroconversion rate of 85.3%, four doses elicited a GMC of 157.44 microg/mL and 67.9% and the sixth of 276.95 microg/mL and 45.5%, respectively. The forth dose elicited 100% seroconversion compared to the pre-immunization level. These results should facilitate comparison between different immunization schedules and new vaccines.
Collapse
Affiliation(s)
- Darrell E Singer
- Division of Retrovirology, Walter Reed Army Institute of Research, Military HIV Research Program, Rockville, MD, USA.
| | | | | | | | | | | |
Collapse
|
10364
|
Abstract
Coronaviruses have the largest known RNA genomes (∼30 kb), which are of positive sense. Together with toroviruses, they are classified in the family Coronaviridae, order Nidovirales. All coronaviruses have four common proteins, three in the envelope and one associated with the genome. Assembly of virus particles occurs at internal membranes. The genes for the structural proteins are at the 3′ end of the genome. Most of the genome (∼20 kb) is gene 1, which encodes 15–16 proteins associated with RNA replication and transcription. Translation of gene 1 involves ribosomal frameshifting. Transcription is by a discontinuous process which results in a 3′ co-terminal nested set of mRNAs, each of which has a common leader sequence transcribed from the 5′ terminus of the genome. Only the most 5′-proximal gene of each mRNA is translated. Recombination is a feature of coronavirus evolution. The outbreak of severe acute respiratory syndrome (SARS) has resulted in the discovery of more coronaviruses in humans, other mammals, and avian species, and the realization that the host range of coronaviruses is wider than previously acknowledged. Coronaviruses are associated with a wide range of diseases, including the respiratory and enteric systems, though not necessarily restricted to these, for example, some coronaviruses affect the central nervous system, kidneys, and gonads. The most widely used coronavirus vaccine (billions of doses annually) is against infectious bronchitis virus, which affects chickens.
Collapse
|
10365
|
McCullers JA, Dunn JD. Advances in vaccine technology and their impact on managed care. P T 2008; 33:35-41. [PMID: 19749990 PMCID: PMC2730064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Accepted: 12/04/2007] [Indexed: 05/28/2023]
Abstract
The discovery of vaccines has led to the near eradication of several important diseases and has had a tremendous impact on health for a relatively low cost. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace.In the past, options for the utilization of vaccines in the area of managed care had been quite limited because of the historically straightforward application of immunizations. The growing number and type of vaccine targets, coupled with novel, more effective formulations, adjuvants, and routes of delivery for vaccines, will undoubtedly create new challenges. Although progress in vaccine technology has the potential to prevent illness and reduce the economic burden of diseases in the long term, thereby improving outcomes, ongoing problems remain in the short term.Who should and will pay for these anticipated improvements in health?How will this period of change be managed?This article describes the present "vaccine revolution" and attempts to answer these questions, which are becoming increasingly important in managed care.
Collapse
|
10366
|
Montoya I. [Immunotherapies for drug addictions]. Adicciones 2008; 20:111-115. [PMID: 18551223 PMCID: PMC2633931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Immunotherapies in the form of vaccines (active immunization) or monoclonal antibodies (passive immunization) appear safe and a promising treatment approaches for some substance-related disorders. The mechanism of action of the antibody therapy is by preventing the rapid entry of drugs of abuse into the central nervous system. In theory, immunotherapies could have several clinical applications. Monoclonal antibodies may be useful to treat drug overdoses and prevent the neurotoxic effects of drugs by blocking the access of drugs to the brain. Vaccines may help to prevent the development of addiction, initiate drug abstinence in those already addicted to drugs, or prevent drug use relapse by reducing the pharmacological effects and rewarding properties of the drugs of abuse on the brain. Passive immunization with monoclonal antibodies has been investigated for cocaine, methamphetamine, nicotine, and phencyclidine (PCP). Active immunization with vaccines has been studied for cocaine, heroin, methamphetamine, and nicotine. These immunotherapies seem promising therapeutic tools and are at different stages in their development before they can be approved by regulatory agencies for the treatment of substance-related disorders. The purpose of this article is to review the current immunotherapy approaches with emphasis on the risks and benefits for the treatment of these disorders.
Collapse
|
10367
|
Lai L, Vödrös D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, Villinger F, Wyatt LS, Moss B, Amara RR, Robinson HL. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007; 369:153-67. [PMID: 17698160 PMCID: PMC2215061 DOI: 10.1016/j.virol.2007.07.017] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2007] [Revised: 07/03/2007] [Accepted: 07/11/2007] [Indexed: 12/01/2022]
Abstract
Single intradermal or intramuscular inoculations of GM-CSF DNA with the DNA prime for a simian-human immunodeficiency virus (SHIV)-89.6 vaccine, which consists of DNA priming followed by modified vaccinia Ankara (MVA) boosting, increased protection of both the blood and intestines against the acute phase of an intrarectal SHIV-89.6P challenge. GM-CSF appeared to contribute to protection by enhancing two antibody responses: the avidity maturation of anti-Env IgG in blood (p=or<0.01) and the presence of long lasting anti-viral IgA in rectal secretions (p<0.01). The avidity of anti-Env IgG showed strong correlations with protection both pre and post challenge. Animals with the highest avidity anti-Env Ab had 1000-fold reductions in peak viremia over those with the lowest avidity anti-Env Ab. The enhanced IgA response was associated with the best protection, but did not achieve significance.
Collapse
Affiliation(s)
- Lilin Lai
- Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA; Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30322, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10368
|
Abstract
Epidemiologic, clinical, morphologic and molecular evidence show that high risk HPV, particularly type 16, is a prerequisite for some carcinomas of the upper aerodigestive tract (UADT), particularly tonsil and base of tongue. Sexual transmission is an important mode of infection while tobacco use and excessive drinking are not considered risk factors. HPV + tumors are distinct clinically and pathologically. They are more common in young patients (<40 years) with a male to female ratio of 4:1. They usually present as a small or occult primary tumor with advanced neck disease. Microscopically they are non-keratinizing squamous cell carcinomas with basaloid features, excessive mitosis and comedo type necrosis. The tumors have a distinct immunohistochemical profile characterized by strong and diffuse p16 reactivity, low or negative p53 staining and high Ki67 labeling scores. HPV + carcinomas are more radio-sensitive and have a better prognosis than the classical keratinizing SCC of the UADT. An anti-HPV vaccine has recently been made available for prevention of cervical cancer. The impact of the vaccine on the prevalence of HPV related carcinomas of the UADT is currently not known but likely beneficial.
Collapse
|
10369
|
Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol Immunother 2007; 56:1921-30. [PMID: 17619878 PMCID: PMC11030789 DOI: 10.1007/s00262-007-0335-y] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2006] [Accepted: 02/05/2007] [Indexed: 10/23/2022]
Abstract
We have shown the immunogenicity and safety of synthetic carbohydrate vaccines when conjugated to the carrier keyhole limpet hemocyanin (KLH) and given with the adjuvant, QS-21, in patients with biochemically relapsed prostate cancer. To determine whether immune response could be further enhanced with stimulation by multiple antigens, a hexavalent vaccine was prepared using previously determined doses and administered in a Phase II setting to 30 high-risk patients. The hexavalent vaccine included GM2, Globo H, Lewis(y), glycosylated MUC-1-32mer and Tn and TF in a clustered formation, conjugated to KLH and mixed with QS-21. Eight vaccinations were administered over 13 months. All 30 patients had significant elevations in antibody titers to at least two of the six antigens; 22 patients had increased reactivity with FACS. These serologic responses were lower than that seen previously in patients treated with the respective monovalent vaccines. The reciprocal median combined IgM and IgG antibody titers with ELISA against MUC1, Tn, TF, globo H and GM2 for these 30 patients were 640, 80, 120, 40 and 0, compared to 1280, 640, 1280, 320 and 160 seen in patients receiving individual monovalent vaccines. This hexavalent vaccine of synthetic "self" antigens broke immunologic tolerance against two or more antigens in all 30 vaccinated patients, was safe, but antibody titers against several of the antigens were lower than those seen in individual monovalent trials. No impact on PSA slope was detected. We address the relevance of the multivalent approach for prostate cancer treatment.
Collapse
Affiliation(s)
- Susan F Slovin
- Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10370
|
Klinman DM, Currie D, Lee G, Grippe V, Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect 2007; 9:1478-83. [PMID: 17913545 PMCID: PMC2117355 DOI: 10.1016/j.micinf.2007.08.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2007] [Revised: 07/26/2007] [Accepted: 08/03/2007] [Indexed: 11/19/2022]
Abstract
Improved vaccines and adjuvants are being developed to reduce the threat posed by a terrorist attack involving aerosolized anthrax spores. Nevertheless, uncertainty persists concerning the relative benefits of inducing mucosal vs systemic immunity to host survival following inhalational exposure to anthrax spores. This work examines the effect of delivering the licensed human vaccine (anthrax vaccine adsorbed, AVA) combined with a CpG oligodeoxynucleotide (ODN) adjuvant intraperitoneally or intranasally to A/J mice. Results indicate that protection from inhalational anthrax correlates with the induction of a strong systemic rather than mucosal immune response, and demonstrate that protection is significantly improved and accelerated by the addition of CpG ODN.
Collapse
Affiliation(s)
- Dennis M Klinman
- Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702, USA.
| | | | | | | | | |
Collapse
|
10371
|
He Y, Falo LD. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 2007; 9:439-446. [PMID: 17932808 PMCID: PMC3065304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
T-cell-mediated immunity is critical for the prevention and control of a broad range of infectious diseases and human malignancies. Genetic immunization is a promising approach for the elicitation of T-cell immunity. Recombinant lentivectors are now being developed and evaluated as antigen delivery platforms for genetic immunization and immune engineering. Early results from studies utilizing lentivectors are promising. Third generation lentivectors have been engineered to improve biosafety and reduce antivector immune responses. The ability of third generation lentivectors to efficiently transduce non-dividing cells, including dendritic cells, suggests important advantages over other antigen delivery platforms. Studies suggest that immunization with lentivectors induces remarkably potent and durable primary and memory T-cell immunity. The combination of skin-targeted immunization and potentially unique mechanisms of immune induction likely contribute to the potent immunogenicity observed. Taken together, this accumulating evidence supports the ongoing development and clinical translation of lentivector-based genetic immunization strategies.
Collapse
Affiliation(s)
| | - Louis D. Falo
- To whom correspondence should be addressed: Louis D. Falo, Jr., MD, PhD., Professor and Chairman, Department of Dermatology, University of Pittsburgh School of Medicine, 145 Lothrop Hall, 190 Lothrop Street, Pittsburgh, PA. 15213, , Telephone: 412-648-3252, Fax: 412-648-8117
| |
Collapse
|
10372
|
Pozsgay V, Kubler-Kielb J, Schneerson R, Robbins JB. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci U S A 2007; 104:14478-82. [PMID: 17726093 PMCID: PMC1955462 DOI: 10.1073/pnas.0706969104] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2007] [Indexed: 11/18/2022] Open
Abstract
Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.
Collapse
Affiliation(s)
- Vince Pozsgay
- Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423
| | - Joanna Kubler-Kielb
- Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423
| | - Rachel Schneerson
- Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423
| | - John B. Robbins
- Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423
| |
Collapse
|
10373
|
Jin B, Wang RY, Qiu Q, Sugauchi F, Grandinetti T, Alter HJ, Shih JWK. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 2007; 122:15-27. [PMID: 17451465 PMCID: PMC2265985 DOI: 10.1111/j.1365-2567.2007.02607.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Double-stranded RNA is produced during virus replication and, together with the viral antigen, is responsible for inducing host antivirus immunity. The hepatitis C virus (HCV) non-structural protein-3 (NS3) has been implicated in the immune evasion of HCV, and is one of the prime targets for inducing immunity against HCV infection. Mice were immunized with recombinant NS3 protein (rNS3) and poly (I:C) emulsified in Montanide ISA 720 (M720). Cytokine production was assayed by enzyme-linked immunospot assay, and CD4(+) IFN-gamma(+) T helper (Th) cells or CD8(+) IFN-gamma(+) cytotoxic T lymphocytes were detected by flow cytometry. Anti-NS3 titre and immunoglobulin G2a (IgG2a) and IgG1 levels were monitored by enzyme-linked immunosorbent assay. Administration of rNS3 formulated in poly (I:C) and M720 induced anti-NS3 titres with a predominantly IgG2a isotype comparable to those induced by rNS3 in CpG-ODN and M720. The cytokine profiles showed that this formulation induced a Th1-biased immune response with several-fold more interferon-gamma (IFN-gamma)-producing cells than interleukin-4-producing cells. In contrast, rNS3 in M720 induced a Th2-biased immune response. The frequency of IFN-gamma-producing CD4(+) and CD8(+) cells induced by rNS3 in poly (I:C) and M720 was significantly higher than that induced by rNS3, rNS3 in M720, or rNS3 in poly (I:C), and was comparable to that induced by rNS3 in CpG-ODN with M720. The antigen-specific CD8(+) T-cell immune response persisted for up to 7 months after immunization. In conclusion, poly (I:C) with rNS3 in M720 can elicit a strong and persistent Th1-biased immune response and a cytotoxic T-lymphocyte response through cross-priming in mice. This study highlighted a promising formulation for inducing an efficient cellular immune response against HCV that has potential for HCV vaccine development.
Collapse
Affiliation(s)
- Bo Jin
- Infectious Disease Section, Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
| | | | | | | | | | | | | |
Collapse
|
10374
|
Abstract
Regulatory T (T(reg)) cells show promise for treating autoimmune diseases, but their induction to elevated potency has been problematic when the most optimally derived cells are from diseased animals. To circumvent reliance on auto-antigen reactive T(reg) cells, stimulation to vaccine antigens (Ags) may offer a viable alternative while maintaining potency to protect against proinflammatory diseases. Our Salmonella vaccine expressing colonization factor Ag I (CFA/I) possesses anti-inflammatory properties, evident by elevated Th2 cell responses, reduced inflammatory cell infiltrates in the Peyer's patches, and an absence of proinflammatory cytokine production by infected macrophages. Given these findings, we hypothesized whether this vaccine would be protective against experimental autoimmune encephalomyelitis (EAE). As such, Salmonella-CFA/I protected in both prophylactic and therapeutic paradigms against proteolipid protein (PLP(139-151))-mediated EAE in SJL mice. The protected mice showed significantly reduced clinical disease and subsequent resolution when compared to PBS-treated controls. Histopathological studies showed reduced demyelination and no inflammation of spinal cords when compared to PBS- or Salmonella vector-treated mice. To ascertain whether the observed immune deviation was in part supported by T(reg) cells, analysis revealed involvement of FoxP3(+) CD25(+) CD4(+) T cells. Adoptive transfer of induced TGF-beta (+) T(reg) cells from vaccinated mice showed complete protection against PLP(139-151) challenge, but not by naive T(reg) cells. Partial protection to EAE was also achieved by the adoptive transfer of CD25(-) CD4(+) T cells, suggesting that Th2 cells also contributed. Thus, these data show that T(reg) cells are induced by oral vaccination with Salmonella-CFA/I contributing to the efficacious treatment of autoimmune disease.
Collapse
Affiliation(s)
- D W Pascual
- Veterinary Molecular Biology, Montana State University, Bozeman, Montana 59717-3610, USA.
| | | | | | | |
Collapse
|
10375
|
Chakraborty M, Schlom J, Hodge JW. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother 2007; 56:1471-84. [PMID: 17318654 PMCID: PMC11031104 DOI: 10.1007/s00262-007-0291-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2006] [Accepted: 01/11/2007] [Indexed: 10/23/2022]
Abstract
Blockade of CTLA-4 by monoclonal antibodies (mAb) can mediate regression of tumors and increase the efficacy of tumor antigen specific vaccines. Blockade of CTLA-4 has also been shown to significantly increase the avidity of antigen-specific T cells after immunization with live recombinant viral vector based vaccine. Here, we demonstrate a biological synergy between CTLA-4 blockade and active vaccine therapy consisting of recombinant vaccinia and avipox viruses expressing carcinoembryonic antigen (CEA) and three T cell costimulatory molecules to enhance antitumor effects. However, this synergy was very much dependent on the temporal relationship of scheduling of the two agents. We evaluated the strategies in both a foreign antigen model using beta-galactosidase as immunogen, and in a "self" antigen model using CEA as immunogen. For antitumor activity the model used consisted of mice transgenic for human CEA and a murine carcinoma cell line transfected with CEA. The enhanced antitumor activity after vaccine and CTLA-4 blockade did not result in any signs of autoimmunity. These studies form a rational basis for the use of vector-based vaccines with anti-CTLA-4 and demonstrate that both enhancement of positive costimulatory signals and inhibition of negative costimulatory signals can be simultaneously exploited. These studies also underscore the importance of "drug" scheduling in vaccine combination therapies.
Collapse
Affiliation(s)
- Mala Chakraborty
- Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Room 8B09, Bethesda, MD 20892 USA
| | - Jeffrey Schlom
- Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Room 8B09, Bethesda, MD 20892 USA
| | - James W. Hodge
- Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Room 8B09, Bethesda, MD 20892 USA
| |
Collapse
|
10376
|
Piver E, Collin C, Vaudin P, Diatta A, Pagès JC. [Alphavirus derived vector, still a relevant system through new mobilisation procedure]. Virologie (Montrouge) 2007; 11:269-278. [PMID: 36131474 DOI: 10.1684/11-4.2011.7285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Among eukaryotic cell-expression-systems, the one derived from alphaviruses, including Semliki forest virus (SFV), offers an efficient method for protein production in mammalian cells. Despite this efficacy, twenty years after their discovery alphaviruses vectors remain poorly used. Alphavirus vectors exist as naked RNA vectors or as recombinant particles. The use of costly RNA-based replicons, and the fact that production of recombinant particles is a complex process to carry out, have hampered the attractiveness of the methods. Lastly, the apoptotic signals induced by alphavirus vectors replication leads to a rapid death of the producing cells. This feature, which can be detrimental in vitro, is advantageously exploited for in vivo applications. Besides laboratory applications, alphavirus vectors have been explored in rare phase I clinical trials, for vaccine development and cancer gene therapy, therefore, alphavirus vector will benefit from the advent of new, biosafety-efficient, methods for particles production. Most of the recent advances in the field proposed an heterologous mobilisation of alphavirus replicon. While increasing biosafety aspects, new methods are also simpler regarding the genesis of recombinant particles. In the present review, we overview the alphavirus life cycle with a special attention to the features influencing vector design and utility.
Collapse
Affiliation(s)
- E Piver
- Université François Rabelais, Inserm ERI19 et Service de biochimie et biologie moléculaire, CHRU, Tours
| | - C Collin
- Université François Rabelais, Inserm ERI19 et Service de biochimie et biologie moléculaire, CHRU, Tours
| | - P Vaudin
- Université François Rabelais, Inserm ERI19 et Service de biochimie et biologie moléculaire, CHRU, Tours
| | - A Diatta
- Université François Rabelais, Inserm ERI19 et Service de biochimie et biologie moléculaire, CHRU, Tours
| | - J-C Pagès
- Université François Rabelais, Inserm ERI19 et Service de biochimie et biologie moléculaire, CHRU, Tours
| |
Collapse
|
10377
|
de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tam Y. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother 2007; 56:1251-64. [PMID: 17242927 PMCID: PMC11030982 DOI: 10.1007/s00262-006-0276-x] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2006] [Accepted: 12/15/2006] [Indexed: 12/19/2022]
Abstract
Immunostimulatory oligodeoxynucleotides (ODN) containing cytosine-guanine (CpG) motifs are powerful stimulators of innate as well as adaptive immune responses, exerting their activity through triggering of the Toll-like receptor 9. We have previously shown that encapsulation in liposomal nanoparticles (LN) enhances the immunostimulatory activity of CpG ODN (LN-CpG ODN) (Mui et al. in J Pharmacol Exp Ther 298:1185, 2001). In this work we investigate the effect of encapsulation on the immunopotency of subcutaneously (s.c.) administered CpG ODN with regard to activation of innate immune cells as well as its ability to act as a vaccine adjuvant with tumor-associated antigens (TAAs) to induce antigen (Ag)-specific, adaptive responses and anti-tumor activity in murine models. It is shown that encapsulation specifically targets CpG ODN for uptake by immune cells. This may provide the basis, at least in part, for the significantly enhanced immunostimulatory activity of LN-CpG ODN, inducing potent innate (as judged by immune cell activation and plasma cytokine/chemokine levels) and adaptive, Ag-specific (as judged by MHC tetramer positive T lymphocytes, IFN-gamma secretion and cytotoxicity) immune responses. Finally, in efficacy studies, it is shown that liposomal encapsulation enhances the ability of CpG ODN to adjuvanate adaptive immune responses against co-administered TAAs after s.c. immunization, inducing effective anti-tumor activity against both model and syngeneic tumor Ags in murine tumor models of thymoma and melanoma.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Adjuvants, Immunologic/pharmacokinetics
- Adjuvants, Immunologic/pharmacology
- Animals
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/pharmacokinetics
- Antineoplastic Agents/pharmacology
- CD8-Positive T-Lymphocytes/drug effects
- CD8-Positive T-Lymphocytes/immunology
- Cancer Vaccines/therapeutic use
- Chemokine CCL2/blood
- Drug Compounding
- Drug Screening Assays, Antitumor
- Female
- Fluorescent Dyes/analysis
- Injections, Subcutaneous
- Interferon-gamma/blood
- Interleukin-10/blood
- Interleukin-6/blood
- Intramolecular Oxidoreductases/immunology
- Liposomes/administration & dosage
- Liposomes/pharmacokinetics
- Lung Neoplasms/secondary
- Lung Neoplasms/therapy
- Lymphocyte Activation/drug effects
- Melanoma, Experimental/immunology
- Melanoma, Experimental/secondary
- Melanoma, Experimental/therapy
- Mice
- Mice, Inbred C57BL
- Mice, Inbred ICR
- Nanoparticles/administration & dosage
- Oligodeoxyribonucleotides/administration & dosage
- Oligodeoxyribonucleotides/pharmacokinetics
- Oligodeoxyribonucleotides/pharmacology
- Ovalbumin/immunology
- Thymoma/immunology
- Thymoma/secondary
- Thymoma/therapy
Collapse
Affiliation(s)
- Susan de Jong
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC Canada
| | - Ghania Chikh
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Laura Sekirov
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Sam Raney
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Sean Semple
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Sandra Klimuk
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Ning Yuan
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Micheal Hope
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| | - Pieter Cullis
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC Canada
| | - Ying Tam
- Inex Pharmaceuticals Corporation, Burnaby, BC Canada
| |
Collapse
|
10378
|
Abstract
Vaccine-induced antibodies that interfere with viral entry are the protective correlate of most existing prophylactic vaccines. However, for highly variable viruses such as HIV-1, the ability to elicit broadly neutralizing antibody responses through vaccination has proven to be extremely difficult. The major targets for HIV-1 neutralizing antibodies are the viral envelope glycoprotein trimers on the surface of the virus that mediate receptor binding and entry. HIV-1 has evolved many mechanisms on the surface of envelope glycoproteins to evade antibody-mediated neutralization, including the masking of conserved regions by glycan, quaternary protein interactions and the presence of immunodominant variable elements. The primary challenge in the development of an HIV-1 vaccine that elicits broadly neutralizing antibodies therefore lies in the design of suitable envelope glycoprotein immunogens that circumvent these barriers. Here, we describe neutralizing determinants on the viral envelope glycoproteins that are defined by their function in receptor binding or by rare neutralizing antibodies isolated from HIV-infected individuals. We also describe the nonvariable cellular receptors involved in the HIV-1 entry process, or other cellular proteins, and ongoing studies to determine if antibodies against these proteins have efficacy as therapeutic reagents or, in some cases, as vaccine targets to interfere with HIV-1 entry.
Collapse
Affiliation(s)
- S Phogat
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | | | | |
Collapse
|
10379
|
Kim M, Qiao Z, Yu J, Montefiori D, Reinherz EL. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 2007; 25:5102-14. [PMID: 17055621 PMCID: PMC2705924 DOI: 10.1016/j.vaccine.2006.09.071] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2006] [Revised: 09/13/2006] [Accepted: 09/15/2006] [Indexed: 11/22/2022]
Abstract
The conserved membrane proximal external region (MPER) of the ectodomain of human immunodeficiency virus type 1 (HIV-1) gp41 is the target of two broadly neutralizing antibodies, 2F5 and 4E10. However, no neutralizing antibodies have been elicited against immunogens bearing these epitopes. Given that structural and biochemical studies suggest that the lipid membrane of the virion is involved in their proper configuration, HIV-1 gp41 derivatives in a pre-fusion state were expressed on the surface of immature virus like particles (VLP) derived from Sf9 cells. Guinea pigs were immunized with three doses of VLPs or Sf9 cells presenting gp41 derivatives with or without E. coli heat-labile enterotoxin (LT) as an adjuvant. While immune sera contained high titer anti-VLP antibodies, the specific anti-gp41 antibody responses were low with no neutralizing antibodies detected. An explanation for this absence may be the low level of gp41 expression relative to the many other proteins derived from host cells which are incorporated onto the VLP surface. In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance.
Collapse
Affiliation(s)
- Mikyung Kim
- Laboratory of Immunobiology and Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts 02115
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115
| | - Zhisong Qiao
- Laboratory of Immunobiology and Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts 02115
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115
| | - Jessica Yu
- Laboratory of Immunobiology and Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts 02115
| | - David Montefiori
- Department of Surgery, Duke University, Medical Center, Durham, North Carolina 27710
| | - Ellis L. Reinherz
- Laboratory of Immunobiology and Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts 02115
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115
| |
Collapse
|
10380
|
Abstract
We report a case of pneumonia in a 13 month old male child with partial DiGeorge syndrome who died after inadvertently receiving live viral vaccines. Although live viral vaccines have been used safely in some children with DiGeorge syndrome, there are insufficient data to recommend their routine use in those with severe immunodeficiency.
Collapse
Affiliation(s)
- V Waters
- Department of Pediatrics, Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, Canada.
| | | | | |
Collapse
|
10381
|
Abstract
Tuberculosis continues to cause considerable human morbidity and mortality worldwide, particularly in people coinfected with HIV. The emergence of multidrug resistance makes the medical treatment of tuberculosis even more difficult. Thus, the development of a tuberculosis vaccine is a global health priority. Here we review the data concerning the role of CD8+ T cells in immunity to tuberculosis and consider how CD8+ T cells can be elicited by vaccination. Many immunization strategies have the potential to elicit CD8+ T cells and we critically review the data supporting a role for vaccine-induced CD8+ T cells in protective immunity. The synergy between CD4+ and CD8+ T cells suggests that a vaccine that elicits both T-cell subsets has the best chance at preventing tuberculosis.
Collapse
Affiliation(s)
- Samuel M. Behar
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Smith Building Room 516C, One Jimmy Fund Way, Boston, MA 02115. Phone: (617)-525-1033, Fax: (617)-525-1010
| | - Joshua S.M. Woodworth
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Smith Building Room 516C, One Jimmy Fund Way, Boston, MA 02115. Phone: (617)-525-1065, Fax: (617)-525-1010
| | - Ying Wu
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Smith Building Room 516C, One Jimmy Fund Way, Boston, MA 02115. Phone: (617)-525-1042, Fax: (617)-525-1010
| |
Collapse
|
10382
|
Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 2007; 25:3859-70. [PMID: 17306426 PMCID: PMC1913199 DOI: 10.1016/j.vaccine.2007.01.100] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2006] [Revised: 01/18/2007] [Accepted: 01/23/2007] [Indexed: 11/28/2022]
Abstract
Infections due to extraintestinal pathogenic E. coli (ExPEC) result in significant morbidity, mortality and increased healthcare costs. An efficacious vaccine against ExPEC would be desirable. In this report, we explore the use of killed-whole E. coli as a vaccine immunogen. Given the diversity of capsule and O-antigens in ExPEC, we have hypothesized that alternative targets are viable vaccine candidates. We have also hypothesized that immunization with a genetically engineered strain that is deficient in the capsule and O-antigen will generate a greater immune response against antigens other than the capsular and O-antigen epitopes than a wild-type strain. Lastly, we hypothesize that mucosal immunization with killed E. coli has the potential to generate a significant immune response. In this study, we demonstrated that nasal immunization with a formalin-killed ExPEC derivative deficient in capsule and O-antigen results in a significantly greater overall humoral response compared to its wild-type derivative (which demonstrates that capsule and/or the O-antigen impede the development of an optimal humoral immune response) and a significantly greater immune response against non-capsular and O-antigen epitopes. These antibodies also bound to a subset of heterologous ExPEC strains and enhanced neutrophil-mediated bactericidal activity against the homologous and a heterologous strain. Taken together, these studies support the concept that formalin-killed genetically engineered ExPEC derivatives are whole cell vaccine candidates to prevent infections due to ExPEC.
Collapse
Affiliation(s)
- Thomas A Russo
- Department of Medicine, University at Buffalo, and Veterans Administration Western New York Healthcare System, Buffalo, NY 14214, United States.
| | | | | | | | | | | | | | | | | |
Collapse
|
10383
|
Heinrich JE, Pollard M, Wolter WA, Liang Z, Song H, Rosen ED, Suckow MA. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats. Cancer Immunol Immunother 2007; 56:725-30. [PMID: 16953436 PMCID: PMC11030641 DOI: 10.1007/s00262-006-0223-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2006] [Accepted: 08/03/2006] [Indexed: 11/26/2022]
Abstract
Reducing expression of the tissue factor gene in prostate adenocarcinoma cells (PAIII) results in a cell line that, in vivo, mimics the growth of wildtype (wt) PAIII. However, instead of continuing to grow and metastasize as wt PAIII tumors do, tissue factor deficient PAIII (TFD PAIII) masses spontaneously regress after several weeks. Although whole cell vaccines are typically inactivated prior to administration to prevent proliferation within the host, numerous studies have suggested that exposure to live, attenuated, whole tumor cells, and the extracellular microenvironment they recruit, increases immunotherapeutic potential. Here, we provide support for this notion, and a strategy through which to implement it, by demonstrating that subcutaneous vaccinations with the TFD PAIII protect the Lobund-Wistar rat against subsequent wt PAIII cell challenge. TFD PAIII immunized rats suffered significantly less metastasis of wt PAIII challenge tumors compared to unvaccinated naïve controls rats. These results offer the intriguing possibility that the TFD PAIII vaccine is an effective system for the prevention and, possibly, the treatment of prostate cancer.
Collapse
Affiliation(s)
- Julie E Heinrich
- University of Notre Dame Biological Sciences, Notre Dame, IN, USA.
| | | | | | | | | | | | | |
Collapse
|
10384
|
Abstract
The unique antigenic determinants (Idiotype [Id]) of the immunoglobulin expressed on a given B-cell malignancy can serve as a tumor-specific antigen for active immunotherapy. Therapeutic vaccines targeting the tumor-specific idiotype have demonstrated promising results against lymphomas in phase I/II studies and are currently being evaluated in phase III randomized trials. Additional vaccine therapies being developed include those based on DNA, dendritic cells, gene-modified tumor cells. It is hoped that immunotherapeutic agents, used in tandem or in combination, may in the future allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies.
Collapse
Affiliation(s)
- Seung-Tae Lee
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
| | - Sattva S. Neelapu
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
| | - Larry W. Kwak
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
10385
|
Pozsgay V, Kubler-Kielb J. Synthesis of an experimental glycolipoprotein vaccine against Lyme disease. Carbohydr Res 2007; 342:621-6. [PMID: 17182019 PMCID: PMC2709212 DOI: 10.1016/j.carres.2006.11.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2006] [Revised: 11/07/2006] [Accepted: 11/08/2006] [Indexed: 11/17/2022]
Abstract
A novel glycolipid was synthesized that corresponds to cholesteryl palmitoyl-galactopyranoside 1 found in the spirochete Borrelia burgdorferi, the causative agent of Lyme disease. In order to fashion 1 in a conjugatable form, the palmitoyl residue was modified to include a terminal aldehydo moiety that anchored the glycolipid to aminooxypropylated serum albumin using oxime chemistry. The glycolipoprotein so obtained incorporates an average of 18 glycolipid moieties per albumin molecule. The novel glycolipoprotein constructs are soluble in water and are candidates toward developing a semisynthetic vaccine against Lyme disease.
Collapse
Affiliation(s)
- Vince Pozsgay
- Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA.
| | | |
Collapse
|
10386
|
Patel JA, Nguyen DT, Revai K, Chonmaitree T. Role of respiratory syncytial virus in acute otitis media: implications for vaccine development. Vaccine 2007; 25:1683-9. [PMID: 17156899 PMCID: PMC1828634 DOI: 10.1016/j.vaccine.2006.10.045] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 10/12/2006] [Accepted: 10/20/2006] [Indexed: 11/18/2022]
Abstract
We summarize herein the results of various virologic studies of acute otitis media (AOM) conducted at our site over a 10-year period. Among 566 children with AOM, respiratory syncytial virus (RSV) was the most common virus identified in either middle ear fluid or nasal wash; it was found in 16% of all children and 38% of virus-positive children. Seventy-one percent of the children with RSV were 1 year of age or older, which was significantly older than all other viruses combined (P=0.045). RSV infection was associated with the common bacterial pathogens causing AOM. Past efforts to develop vaccines for RSV have emphasized prevention of lower respiratory tract infection in infants, which is a more serious problem but less common than AOM. Our results suggest that RSV vaccines that work only against infection in older children may have value in preventing AOM, the most common pediatric disease.
Collapse
Affiliation(s)
- Janak A Patel
- Departments of Pediatrics, University of Texas Medical Branch, Galveston, TX 77555-0371, United States.
| | | | | | | |
Collapse
|
10387
|
Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, Nussenzweig MC, Piperno AG, Steinman RM. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 2007; 104:1289-94. [PMID: 17229838 PMCID: PMC1783096 DOI: 10.1073/pnas.0610383104] [Citation(s) in RCA: 188] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2006] [Indexed: 11/18/2022] Open
Abstract
Optimal HIV vaccines should elicit CD8+ T cells specific for HIV proteins presented on MHC class I products, because these T cells contribute to host resistance to viruses. We had previously found that the targeting of antigen to dendritic cells (DCs) in mice efficiently induces CD8+ T cell responses. To extend this finding to humans, we introduced the HIV p24 gag protein into a mAb that targets DEC-205/CD205, an endocytic receptor of DCs. We then assessed cross-presentation, which is the processing of nonreplicating internalized antigen onto MHC class I for recognition by CD8+ T cells. Low doses of alphaDEC-gag, but not control Ig-gag, stimulated proliferation and IFN-gamma production by CD8+ T cells isolated from the blood of HIV-infected donors. alphaCD205 fusion mAb was more effective for cross-presentation than alphaCD209/DC-SIGN, another abundant DC uptake receptor. Presentation was diverse, because we identified eight different gag peptides that were recognized via DEC-205 in 11 individuals studied consecutively. Our results, based on humans with highly polymorphic MHC products, reveal that DCs and DEC-205 can cross-present several different peptides from a single protein. Because of the consistency in eliciting CD8+ T cell responses, these data support the testing of alphaDEC-205 fusion mAb as a protein-based vaccine.
Collapse
Affiliation(s)
| | | | - Frederick P. Siegal
- Comprehensive HIV Center, Saint Vincent's Hospital and Medical Center, New York, NY 10011
| | - Saurabh Mehandru
- The Rockefeller University Hospital and Aaron Diamond AIDS Research Center, New York, NY 10011; and
| | - Martin Markowitz
- The Rockefeller University Hospital and Aaron Diamond AIDS Research Center, New York, NY 10011; and
| | - Mary Carrington
- Laboratory of Genomic Diversity, SAIC-Frederick, Inc., National Cancer Institute, Frederick, MD 21702
| | - Michel C. Nussenzweig
- Molecular Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10021
| | | | | |
Collapse
|
10388
|
Wang Z, La Rosa C, Li Z, Ly H, Krishnan A, Martinez J, Britt WJ, Diamond D. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 2007; 25:1132-41. [PMID: 17049414 PMCID: PMC1852509 DOI: 10.1016/j.vaccine.2006.09.067] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2006] [Revised: 08/17/2006] [Accepted: 09/13/2006] [Indexed: 11/21/2022]
Abstract
CMV tegument protein pp65 and CMV immediate early gene product IE1 are both considered immunodominant targets of cell-mediated immunity (CMI) and potentially capable of controlling CMV infection. To better assess their role in host defense, we have constructed a novel MVA transfer vector named pZWIIA and generated a recombinant MVA (rMVA) expressing both full-length pp65 and exon4 of IE1 (pp65-IE1-MVA) at high levels, followed by the genetic removal of the bacterial marker gene used to distinguish recombinant forms. Immunogenicity evaluation indicates that pp65-IE1-MVA not only can induce robust primary CMI to both antigens in HLA A2.1 Tg mice, but also can stimulate vigorous expansion of memory T lymphocyte responses to pp65 and IE1 in PBMC of CMV-positive donors. These properties make the MVA-based vaccine ideal for the dual role of priming and boosting CMV-specific T cell immunity as a means to control CMV disease in recipients of hematopoietic cell or solid organ transplantation (HCT or SOT). pZWIIA alone or in combination with other MVA transfer vectors can be used to generate MVA based multiple-antigen vaccine which have application in vaccine development for a wide spectrum of infectious diseases and cancer.
Collapse
Affiliation(s)
- Zhongde Wang
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| | - Corinna La Rosa
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| | - Zhongqi Li
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| | - Heang Ly
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| | - Aparna Krishnan
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| | - Joy Martinez
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| | - William J. Britt
- Department of Pediatrics, University of Alabama, Birmingham, Alabama 352333
| | - Don Diamond
- Laboratory of Vaccine Research, Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA 91010
| |
Collapse
|
10389
|
Ubaidulla U, Reddy MVS, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSciTech 2007; 8:2. [PMID: 17408218 PMCID: PMC2750667 DOI: 10.1208/pt0801002] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2007] [Revised: 09/20/2007] [Accepted: 09/24/2007] [Indexed: 11/30/2022] Open
Abstract
The purpose of this research was to develop a matrix-type transdermal therapeutic system containing carvedilol with different ratios of hydrophilic and hydrophobic polymeric combinations by the solvent evaporation technique. The physicochemical compatibility of the drug and the polymers was studied by infrared spectroscopy and differential scanning calorimetry. The results suggested no physicochemical incompatibility between the drug and the polymers. In vitro permeation studies were performed by using Franz diffusion cells. The results followed Higuchi kinetics (r = 0.9953-0.9979), and the mechanism of release was diffusion mediated. Based on physicochemical and in vitro skin permeation studies, patches coded as F3 (ethyl cellulose:polyvinylpyrrolidone, 7.5:2.5) and F6 (Eudragit RL:Eudragit RS, 8:2) were chosen for further in vivo studies. The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration. The antihypertensive activity of the patches in comparison with that of oral carvedilol was studied using methyl prednisolone acetate-induced hypertensive rats. It was observed that both the patches significantly controlled hypertension from the first hour (P < .05). The developed transdermal patches increase the efficacy of carvedilol for the therapy of hypertension.
Collapse
Affiliation(s)
- Udhumansha Ubaidulla
- Faculty of Pharmacy, Jamia University, Department of Pharmaceutics, New Delhi, India.
| | | | | | | | | |
Collapse
|
10390
|
Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB, Schneerson R. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 2007; 104:293-8. [PMID: 17190797 PMCID: PMC1765452 DOI: 10.1073/pnas.0609885104] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2006] [Indexed: 11/18/2022] Open
Abstract
Malaria is a leading cause of morbidity and mortality, estimated to cause >1 million childhood deaths annually. Plasmodium falciparum causes the most severe form of the disease. There is as yet no licensed vaccine for this disease, despite over a half century of research. In this study, we investigated a transmission-blocking vaccine candidate, the ookinete surface protein Pfs25. Antibodies against Pfs25, drawn in during a bite, can block parasite development in the mosquito midgut, preventing transmission to other individuals. Pfs25 is a low-molecular-weight protein, by itself not immunogenic. To increase its immunogenicity, we investigated several methods of conjugating Pfs25 to itself and to other proteins: recombinant Pseudomonas aeruginosa exotoxin A, and ovalbumin, using amide, hydrazone, or thioether linkages. All conjugates were immunogenic and induced booster responses in mice. The scheme to form amide bonds between proteins by using adipic acid dihydrizide as a linker produced the most immunogenic conjugates. Adsorption of the conjugates onto aluminum hydroxide further increased the antibody response. Remarkably, the antibody levels 3 or 7 months after the last injection were significantly higher than those 1 wk after that injection. The observed transmission-blocking activity of immune sera correlated with antibody levels measured by ELISA.
Collapse
Affiliation(s)
- Joanna Kubler-Kielb
- *Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892-2520
| | - Fathy Majadly
- *Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892-2520
| | - Yimin Wu
- Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, MSC 8152, Rockville, MD 20852; and
| | - David L. Narum
- Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, MSC 8152, Rockville, MD 20852; and
| | - Chunyan Guo
- *Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892-2520
| | - Louis H. Miller
- Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, MSC 8152, Rockville, MD 20852; and
| | - Joseph Shiloach
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 14A, Room 173, MSC 5522, Bethesda, MD 20892
| | - John B. Robbins
- *Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892-2520
| | - Rachel Schneerson
- *Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892-2520
| |
Collapse
|
10391
|
Hovden AO, Cox RJ, Haaheim LR. Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2:229-40. [PMID: 18229561 PMCID: PMC2695195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Influenza is a major respiratory pathogen, which exerts a huge human and economic toll on society. Influenza is a vaccine preventable disease, however, the vaccine strains must be annually updated due to the continuous antigenic changes in the virus. Inactivated influenza vaccines have been used for over 50 years and have an excellent safety record. Annual vaccination is therefore recommended for all individuals with serious medical conditions, like COPD, and protects the vaccinee against influenza illness and also against hospitalization and death. In COPD patients, influenza infection can lead to exacerbations resulting in reduced quality of life, hospitalization and death in the most severe cases. Although there is only limited literature on the use of influenza vaccination solely in COPD patients, there is clearly enough evidence to recommend annual vaccination in this group. This review will focus on influenza virus and prophylaxis with inactivated influenza vaccines in COPD patients and other "at risk" groups to reduce morbidity, save lives, and reduce health care costs.
Collapse
Affiliation(s)
- Arnt-Ove Hovden
- The Influenza Centre, The Gade Institute, Faculty of Medicine, University of Bergen, Bergen, Norway.
| | | | | |
Collapse
|
10392
|
Abstract
Vaccination is one of the most efficient ways to eradicate some infectious diseases in humans and animals. The material traditionally used as vaccines is attenuated or inactivated pathogens. This approach is sometimes limited by the fact that the material for vaccination is not efficient, not available, or generating deleterious side effects. A possible theoretical alternative is the use of recombinant proteins from the pathogens. This implies that the proteins having the capacity to vaccinate have been identified and that they can be produced in sufficient quantity at a low cost. Genetically modified organisms harboring pathogen genes can fulfil these conditions. Microorganisms, animal cells as well as transgenic plants and animals can be the source of recombinant vaccines. Each of these systems that are all getting improved has advantages and limits. Adjuvants must generally be added to the recombinant proteins to enhance their vaccinating capacity. This implies that the proteins used to vaccinate have been purified to avoid any immunization against the contaminants. The efficiency of a recombinant vaccine is poorly predictable. Multiple proteins and various modes of administration must therefore be empirically evaluated on a case-by-case basis. The structure of the recombinant proteins, the composition of the adjuvants and the mode of administration of the vaccines have a strong and not fully predictable impact on the immune response as well as the protection level against pathogens. Recombinant proteins can theoretically also be used as carriers for epitopes from other pathogens. The increasing knowledge of pathogen genomes and the availability of efficient systems to prepare large amounts of recombinant proteins greatly facilitate the potential use of recombinant proteins as vaccines. The present review is a critical analysis of the state of the art in this field.
Collapse
Affiliation(s)
- Eric Soler
- Cell Biology Department, Erasmus MC, dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.
| | | |
Collapse
|
10393
|
Abstract
Patients and clinicians experience the frustration of cutaneous viral warts caused by infection with the human papilloma virus (HPV).Warts appear in various forms on different sites of the body and include common warts (verruca vulgaris), plane or flat warts, myrmecia, plantar warts, coalesced mosaic warts, filiform warts, periungual warts, anogenital warts (venereal or condyloma acuminata), oral warts and respiratory papillomas. Cervical infection with HPV is now known to cause cervical cancer if untreated. A review of the medical literature reveals a huge armamentarium of wart monotherapies and combination therapies. Official evidence-based guidelines exist for the treatment of warts, but very few of the reported treatments have been tested by rigorous blinded, randomized controlled trials.Therefore, official recommendations do not often include treatments with reportedly high success rates, but they should not be ignored when considering treatment options. It is the purpose of this review to provide a comprehensive overview of the wart treatment literature to expand awareness of the options available to practitioners faced with patients presenting with problematic warts.
Collapse
Affiliation(s)
- Michelle M Lipke
- MPAS, PA-C, Department of Dermatology, Marshfield Clinic-Wausau Center, Wausau, WI 54401, USA.
| |
Collapse
|
10394
|
Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006; 55:1491-503. [PMID: 16485128 PMCID: PMC11030856 DOI: 10.1007/s00262-006-0138-6] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2005] [Accepted: 12/30/2005] [Indexed: 11/30/2022]
Abstract
Survivin is a member of the inhibitor of apoptosis protein family. Gliomas and many other tumors express survivin at high levels; whereas, normal fully differentiated cells generally do not. Therefore, survivin represents a tumor-specific target for cancer vaccine therapy. It has been shown that it is possible to produce a MHC-I-restricted cellular immunologic response to survivin vaccines. To study differences in immunogenicity between murine and human survivin proteins, we vaccinated C57BL/6 mice with bone marrow dendritic cells (BMDC) transfected with expression vectors containing the murine and human survivin genes. Mice vaccinated with BMDCs expressing a truncated human survivin protein developed cytotoxic T lymphocyte to subcutaneous GL261 glioma cells and exhibited prolonged tumor-free survival compared to mice vaccinated with BMDCs transfected with vector alone (P<0.01). While mice challenged with intracerebral GL261 cells had increased survival, no cures were observed. In contrast, vaccinated mice that fully resisted subcutaneous tumor challenge were rendered resistant to intracerebral GL261 re-challenge. BMDCs transfected with the full-length human survivin molecule were significantly more effective at prolonging survival than BMDCs expressing the full-length murine survivin gene (P=0.0175). Therefore, xenogeneic differences between human and murine sequences might be exploited to develop more immunogenic tumor vaccines.
Collapse
Affiliation(s)
- Michael J Ciesielski
- Departments of Neurosurgery and Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
| | | | | | | | | | | |
Collapse
|
10395
|
Bégué P. [Varicella and zoster vaccines]. Virologie (Montrouge) 2006; 10:407-14. [PMID: 34753241 DOI: 10.1684/vir.2011.8640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The varicella vaccine (OKA strain) first used in Japan in 70's was introduced into the routine infants immunisation schedule of United States in 1995. Two other new varicella vaccines have been just licensed: a tetravalent measles-mumps-rubella-varicella vaccine (MMRV) and a zoster vaccine for more than 60 years old adults. In Europe varicella vaccine is not introduced in routine infant schedule, except in Germany, and only used for targeted aims. This reluctance is justified by several considerations: the fear of a shift of varicella to adults by low vaccine coverage, the risk of increasing zoster in adults by a mass vaccination. Several recent varicella outbreaks in highly vaccinated children stress the possible need for a routine second dose of vaccine in infants. The cost-effectiveness studies results are not similar in different countries and the benefits are indirect (time off work).Varicella is often considered as a mild disease, in spite of a better knowledge of complications and health benefits in United-States, where vaccination has resulted in a dramatic decline of deaths, hospitalisations and varicella-related complications. The new tetravalent MMRV vaccine could stimulate Europe to implement routine vaccination, provided that an efficient surveillance for varicella and shingles be instituted.
Collapse
|
10396
|
Abstract
Premature infants are at increased risk of vaccine preventable infections, but audits have shown that their vaccinations are often delayed. Early protection is desirable. While the evidence base for immunisation of preterm infants is limited, the available data support early immunisation without correction for gestational age. For a number of antigens the antibody response to initial doses may be lower than that of term infants, but protective concentrations are often achieved and memory successfully induced. A 2-3-4 month schedule may be preferable for immunisation of preterm infants in order to achieve protection as early as possible, but an additional dose may be required to achieve persistence of protection. This update focuses on the use of routine childhood vaccines in premature infants.
Collapse
|
10397
|
Abstract
Rotavirus, the most common cause of severe diarrhea and a leading cause of mortality in children, has been a priority target for vaccine development for the past several years. The first rotavirus vaccine licensed in the United States was withdrawn because of an association of the vaccine with intussusception. However, the need for a vaccine is greatest in the developing world, because the benefits of preventing deaths due to rotavirus disease are substantially greater than the risk of intussusception. Early vaccines were based on animal strains. More recently developed and licensed vaccines are either animal-human re-assortants or are based on human strains. In India, two candidate vaccines are in the development process, but have not yet reached efficacy trials. Many challenges regarding vaccine efficacy and safety remain. In addition to completing clinical evaluations of vaccines in development in settings with the highest disease burden and virus diversity, there is also a need to consider alternative vaccine development strategies.
Collapse
Affiliation(s)
- G Kang
- Department of Gastrointestinal Sciences, Christian Medical College, Vellore--632004, Tamilnadu, India.
| |
Collapse
|
10398
|
Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho Z, Ma BJ, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006; 353:268-82. [PMID: 17039602 PMCID: PMC1762135 DOI: 10.1016/j.virol.2006.04.043] [Citation(s) in RCA: 166] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
HIV-1 subtype C is the most common HIV-1 group M subtype in Africa and many parts of Asia. However, to date HIV-1 vaccine candidate immunogens have not induced potent and broadly neutralizing antibodies against subtype C primary isolates. We have used a centralized gene strategy to address HIV-1 diversity and generated a group M consensus envelope gene with shortened consensus variable loops (CON-S) for comparative studies with wild-type (WT) Env immunogens. Our results indicate that the consensus HIV-1 group M CON-S Env elicited cross-subtype neutralizing antibodies of similar or greater breadth and titer than the WT Envs tested, indicating the utility of a centralized gene strategy. Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes.
Collapse
Affiliation(s)
- Hua-Xin Liao
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10399
|
Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 2006; 55:1122-31. [PMID: 16273350 PMCID: PMC11030959 DOI: 10.1007/s00262-005-0089-3] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2005] [Accepted: 09/28/2005] [Indexed: 12/16/2022]
Abstract
Recent reports revealed that dendritic cell (DC)-natural killer (NK) cell interaction plays an important role in tumor immunity, but few DC vaccine studies have attempted to evaluate the non-specific, yet potentially clinically relevant, NK response to immunization. In this study, we first analyzed in vitro activation of NK cells by DCs similar to those used in clinical trials. Subsequently, NK cell responses were analyzed in a phase I clinical trial of a vaccine consisting of autologous DCs loaded with a fowlpox vector encoding CEA. The data were compared with the clinical outcome of the patients. DC enhances NK activity in vitro, partly by sustaining NK cell survival and by enhancing the expression of NK-activating receptors, including NKp46 and NKG2D. Among nine patients in our clinical trial, NK cytolytic activity increased in four (range 2.5-5 times greater lytic activity) including three who had increased NK cell frequency, was stable in two and decreased in three. NKp46 and NKG2D expression showed a good correlation with the patients' NK activity. When patients were grouped by clinical activity (stable disease/no evidence of disease (stable/NE, n=5) vs progressive disease (N=4) at 3 months), the majority in the stable/NE group had increases in NK activity (P=0.016). Anti-CEA T cell response was enhanced in all the nine patients analyzed, but was not significantly different between the two groups (P=0.14). Thus, NK responses following DC vaccination may correlate more closely with clinical outcome than do T cell responses. Monitoring of NK response during vaccine studies should be routinely performed.
Collapse
Affiliation(s)
- Takuya Osada
- Duke University Medical Center, Box 3233, Durham, NC 27710 USA
| | - Timothy Clay
- Duke University Medical Center, Box 3233, Durham, NC 27710 USA
| | - Amy Hobeika
- Duke University Medical Center, Box 3233, Durham, NC 27710 USA
| | - H. Kim Lyerly
- Duke University Medical Center, Box 3233, Durham, NC 27710 USA
| | | |
Collapse
|
10400
|
Chen X, Wang B, Chang LJ. Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors. Cell Immunol 2006; 243:10-8. [PMID: 17188256 PMCID: PMC1852462 DOI: 10.1016/j.cellimm.2006.11.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2006] [Revised: 09/29/2006] [Accepted: 11/06/2006] [Indexed: 12/01/2022]
Abstract
In this study, we demonstrate that a minimal self-inactivating (SIN) lentiviral vector (LV) that does not encode any human immunodeficiency virus (HIV) genes is able to induce HIV-specific CD4 and CD8 T cell responses after transduction of dendritic cells (DCs). The LV-DC-primed T cells displayed HIV-specific lytic degranulation, as illustrated by acquisition of CD107a/b expression on the cell surface and up-regulation of active caspase 3. HIV-specific cytotoxic T lymphocyte (CTL) response was consistently detected using different assays, and T cell receptors specific to three prominent HIV epitopes, SL9 (Gag peptide: SLYNTVATL), IV9 (Pol peptide: ILKEPVHGV), and MA10 (In peptide: MASDFNLPPV) were detected using HLA-A0201 peptide-tetramers. These results demonstrate that DCs transduced with the minimal SIN-LV can efficiently induce HIV-specific CD4 and CD8 T cell responses. Since LVs are popular gene transfer tools, our results have fundamental implications for future LV applications and DC vaccine development.
Collapse
Affiliation(s)
- Xiaochuan Chen
- Department of Molecular Genetics and Microbiology, Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL 32610-0266, USA
| | - Bei Wang
- Department of Molecular Genetics and Microbiology, Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL 32610-0266, USA
| | - Lung-Ji Chang
- Department of Molecular Genetics and Microbiology, Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL 32610-0266, USA
| |
Collapse
|